K. K. Ballen, E. Gluckman, and H. E. Broxmeyer, Umbilical cord blood transplantation: the first 25 years and beyond, Blood, vol.122, issue.4, pp.491-499, 2013.

J. N. Barker, Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy, Blood, vol.105, issue.3, pp.1343-1350, 2004.

M. R. Verneris, C. G. Brunstein, J. Barker, M. L. Macmillan, T. Defor et al., Relapse risk after umbilical cord blood transplantation: enhanced graftversus-leukemia effect in recipients of 2 units, Blood, vol.114, pp.4293-4302, 2009.

M. Labopin, A. Ruggeri, N. C. Gorin, E. Gluckman, D. Blaise et al., Costeffectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France, haematologica, vol.99, issue.3, pp.535-540, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01325413

V. Rocha, A. Crotta, A. Ruggeri, D. Purtill, K. Boudjedir et al., Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases, Best Pract Res Clin Haematol, vol.23, issue.2, pp.223-232, 2010.

J. E. Wagner, M. Eapen, S. Carter, Y. Wang, K. R. Schultz et al., One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers, N Engl J Med, vol.371, issue.18, pp.1685-94, 2014.

G. Michel, C. Galambrun, A. Sirvent, C. Pochon, B. Bruno et al., Single-vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome, Blood, vol.127, issue.26, pp.3450-3457, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01482531

P. Bader, H. Kreyenberg, G. Henze, C. Eckert, M. Reising et al., Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group, J Clin Oncol, vol.27, issue.3, pp.377-84, 2009.

P. Bader, E. Salzmann-manrique, A. Balduzzi, J. Dalle, A. E. Woolfrey et al., Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL-a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the WesthafenIntercontinental-Group, Blood, vol.128, issue.22, pp.985-985, 2016.

P. Bader, J. Hancock, H. Kreyenberg, N. J. Goulden, D. Niethammer et al., Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL, Leukemia, vol.16, issue.9, pp.1668-72, 2002.

N. Goulden, P. Bader, V. Van-der-velden, J. Moppett, M. Schilham et al., Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia, Br J Haematol, vol.122, issue.1, pp.24-29, 2003.

O. Krejci, V. Van-der-velden, P. Bader, H. Kreyenberg, N. Goulden et al., Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group, Bone Marrow Transplant, vol.32, issue.8, pp.849-51, 2003.

M. W. Schilham, A. Balduzzi, and P. Bader, Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells? Bone Marrow Transplant, vol.35, pp.49-52, 2005.

L. Tucunduva, A. Ruggeri, G. Sanz, S. Furst, J. Cornelissen et al., Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of, Br J Haematol, vol.166, issue.5, pp.749-57, 2014.

L. Sramkova, K. Muzikova, E. Fronkova, O. Krejci, P. Sedlacek et al., Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer, vol.48, pp.93-100, 2007.

F. Milano, T. Gooley, B. Wood, A. Woolfrey, M. E. Flowers et al., CordBlood Transplantation in Patients with Minimal Residual Disease, N Engl J Med, vol.375, issue.10, pp.944-53, 2016.

D. Cilloni, A. Renneville, F. Hermitte, R. K. Hills, S. Daly et al., Realtime quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study, J Clin Oncol, vol.27, issue.31, pp.5195-5201, 2009.

T. A. Gooley, W. Leisenring, J. Crowley, and B. E. Storer, Estimation of failure probabilities in the presence of competing risks: new representations of old estimators, Stat Med, vol.18, issue.6, pp.695-706, 1999.

J. P. Fine and R. J. Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk, J Am Stat Assoc, vol.94, issue.446, pp.496-509, 1999.

E. L. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, J Am Stat Assoc, vol.53, issue.282, p.457, 1958.

A. Ruggeri, G. Michel, J. H. Dalle, M. Caniglia, F. Locatelli et al., Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWPEBMT analysis, Leukemia, vol.26, issue.12, p.2455, 2012.

V. Bachanova, M. Burke, S. Yohe, Q. Cao, K. Sandhu et al., Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.18, issue.6, pp.963-971, 2012.

C. G. Brunstein, J. A. Gutman, D. J. Weisdorf, A. E. Woolfrey, T. E. Defor et al., Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood, Blood, vol.116, issue.22, pp.4693-4702, 2010.

M. Eapen, P. Rubinstein, M. Zhang, C. Stevens, J. Kurtzberg et al., Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. The Lancet, vol.369, pp.1947-54, 2007.

J. A. Gutman, W. Leisenring, F. R. Appelbaum, A. E. Woolfrey, and C. Delaney, Low relapse without excessive transplant related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.15, issue.9, pp.1122-1131, 2009.

M. B. Tomblyn, M. Arora, K. S. Baker, B. R. Blazar, C. G. Brunstein et al., Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome, J Clin Oncol, vol.27, issue.22, pp.3634-3675, 2009.

M. L. Macmillan, D. J. Weisdorf, C. G. Brunstein, Q. Cao, T. E. Defor et al., Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors, Blood, vol.113, issue.11, pp.2410-2415, 2009.

K. M. Page, M. Labopin, A. Ruggeri, G. Michel, C. D. Heredia et al., Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission, Biol Blood Marrow Transplant, vol.23, issue.8, pp.1350-1358, 2017.

J. Kanda, Y. Morishima, S. Terakura, A. Wake, N. Uchida et al., Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation, Leukemia, vol.31, issue.3, pp.663-671, 2017.

C. A. Lindemans, R. Chiesa, P. J. Amrolia, K. Rao, O. Nikolajeva et al., Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome, Blood, vol.123, issue.1, pp.126-132, 2014.

R. Admiraal, C. A. Lindemans, C. Van-kesteren, M. B. Bierings, A. B. Versluijs et al., Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation, Blood, vol.128, issue.23, pp.2734-2741, 2016.

R. J. Soiffer, J. Lerademacher, V. Ho, F. Kan, A. Artz et al., Impact of immune modulation with anti-T-cell antibodies on the outcome of reducedintensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies, Blood, vol.117, issue.25, pp.6963-70, 2011.

Y. Inamoto, F. Kimura, J. Kanda, J. Sugita, K. Ikegame et al., Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide 45 favorable outcomes in some subgroups, Haematologica, 2016.

C. Zheng, Z. Luan, J. Fang, X. Sun, J. Chen et al., Comparison of Conditioning Regimens with or without Antithymocyte Globulin for Unrelated Cord Blood Transplantation in Children with High-Risk or Advanced Hematological Malignancies, Biol Blood Marrow Transplant, vol.21, issue.4, pp.707-719, 2015.

K. K. Ballen, ATG for cord blood transplant: yes or no?, Blood, vol.123, issue.1, pp.7-8, 2014.

R. Admiraal, S. Nierkens, M. A. De-witte, E. J. Petersen, G. Fleurke et al., Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis, Lancet Haematol, vol.4, issue.4, pp.183-191, 2017.

R. Admiraal, C. Van-kesteren, C. M. Jol-van-der-zijde, A. C. Lankester, M. B. Bierings et al., Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis, Lancet Haematol, vol.2, issue.5, pp.194-203, 2015.

R. J. Soiffer, H. T. Kim, J. Mcguirk, M. E. Horwitz, L. Johnston et al., Prospective, randomized, double-blind, phase III clinical trial of anti-tlymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation, J Clin Oncol, vol.35, issue.36, pp.4003-4011, 2017.

D. A. Berry, S. Zhou, H. Higley, L. Mukundan, S. Fu et al., Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis, JAMA Oncol, pp.170580-170580, 2017.

D. Campana, Detection of minimal residual disease in acute lymphoblastic leukemia, 2010.

E. R. Panzer-grümayer, M. Schneider, S. Panzer, K. Fasching, and H. Gadner, Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia, Blood, vol.95, issue.3, pp.790-794, 2000.

E. Coustan-smith, J. Sancho, F. G. Behm, M. L. Hancock, B. I. Razzouk et al., Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia, Blood, vol.100, issue.1, pp.52-58, 2002.

D. Campana, Status of minimal residual disease testing in childhood haematological malignancies, Br J Haematol, vol.143, issue.4, pp.481-489, 2008.

C. Zheng, X. Zhu, B. Tang, L. Zhang, L. Geng et al., The impact of pretransplant minimal residual disease on outcome of intensified myeloablative cord 46 blood transplant for acute myeloid leukemia in first or second complete remission, Leuk Lymphoma, vol.57, issue.6, pp.1398-405, 2016.

V. Van-der-velden, G. Cazzaniga, A. Schrauder, J. Hancock, P. Bader et al., Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data, Leukemia, vol.21, issue.4, p.604, 2007.

G. Kerst, H. Kreyenberg, C. Roth, C. Well, K. Dietz et al., Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR, Br J Haematol, vol.128, issue.6, pp.774-82, 2005.